Clinical remissions and limited toxicity in a first-in-human multicenter study of bb2121, a novel anti-BCMA CAR T cell therapy for relapsed/refractory multiple myeloma. (December 2016) - Berdeja, J.G.; Lin, Y.; Raje, N.; Siegel, D.; Munshi, N.; Turka, A.; Lam, L.P.; Quigley, M.T.; Kochenderfer, J.N.